Table 1.
Characteristics of the Included Sample
| Count | % | Mean (± Standard Deviation) | ||
|---|---|---|---|---|
| Laterality | Right | 86 | 51.8% | |
| Left | 80 | 48.2% | ||
| Diagnosis | AMD | 22 | 13.3% | |
| DME | 109 | 65.7% | ||
| BRVO | 10 | 6.0% | ||
| CRVO | 4 | 2.4% | ||
| PDR | 19 | 11.4% | ||
| Other | 2 | 1.2% | ||
| Injection type | bevacizumab | 81 | 48.8% | |
| Ranibizumab | 35 | 21.1% | ||
| Aflibercept | 49 | 29.5% | ||
| Triamcinolone | 1 | 0.6% | ||
| Total injections | 4.48 (±4.54) | |||
| Frequency of injections completed before lockdown | 1.00 | 13 | 7.8% | |
| 2.00 | 9 | 5.4% | ||
| 3.00 | 141 | 84.9% | ||
| 4.00 | 1 | 0.6% | ||
| 6.00 | 2 | 1.2% | ||
| Injections completed from last scheduled decision before lockdown | 0.00 | 63 | 38.0% | |
| 1.00 | 63 | 38.0% | ||
| 2.00 | 39 | 23.5% | ||
| 3.00 | 1 | 0.6% | ||
| Duration lateness | 60.97 (±24.35) | |||
| Previous steroid injection | Yes | 15 | 9.0% | |
| No | 151 | 91.0% | ||
| Visual acuity before | 0.30 (± 0.24) | |||
| Visual acuity after | 0.32 (±0.26) | |||
| Macular thickness (µm) before | 398.31 (±138.21) | |||
| Macular thickness (µm) after | 370.04 (±150.33) | |||
Abbreviations: AMD, age-related macular degeneration; DME, diabetic macular edema; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; PDR, proliferative diabetic retinopathy.